ACADIA Pharmaceuticals Inc (ACAD)
17.00
+0.18
(+1.07%)
USD |
NASDAQ |
Apr 22, 16:00
16.52
-0.48
(-2.82%)
After-Hours: 07:53
ACADIA Pharmaceuticals Cash from Financing (TTM): 25.13M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 25.13M |
| September 30, 2023 | 21.31M |
| June 30, 2023 | 8.845M |
| March 31, 2023 | 7.198M |
| December 31, 2022 | 8.199M |
| September 30, 2022 | 10.95M |
| June 30, 2022 | 11.73M |
| March 31, 2022 | 12.90M |
| December 31, 2021 | 18.16M |
| September 30, 2021 | 31.92M |
| June 30, 2021 | 42.57M |
| March 31, 2021 | 84.97M |
| December 31, 2020 | 81.00M |
| September 30, 2020 | 105.93M |
| June 30, 2020 | 414.18M |
| March 31, 2020 | 371.42M |
| December 31, 2019 | 371.85M |
| September 30, 2019 | 629.39M |
| June 30, 2019 | 309.64M |
| March 31, 2019 | 307.94M |
| December 31, 2018 | 306.65M |
| September 30, 2018 | 10.84M |
| June 30, 2018 | 18.52M |
| March 31, 2018 | 22.58M |
| December 31, 2017 | 31.19M |
| Date | Value |
|---|---|
| September 30, 2017 | 30.38M |
| June 30, 2017 | 248.56M |
| March 31, 2017 | 262.31M |
| December 31, 2016 | 533.81M |
| September 30, 2016 | 539.16M |
| June 30, 2016 | 314.21M |
| March 31, 2016 | 296.05M |
| December 31, 2015 | 14.50M |
| September 30, 2015 | 7.977M |
| June 30, 2015 | 8.127M |
| March 31, 2015 | 7.248M |
| December 31, 2014 | 203.85M |
| September 30, 2014 | 201.67M |
| June 30, 2014 | 201.36M |
| March 31, 2014 | 309.52M |
| December 31, 2013 | 111.68M |
| September 30, 2013 | 202.29M |
| June 30, 2013 | 208.17M |
| March 31, 2013 | 98.36M |
| December 31, 2012 | 98.17M |
| September 30, 2012 | 7.036M |
| June 30, 2012 | 0.166M |
| March 31, 2012 | 0.156M |
| December 31, 2011 | 13.94M |
| September 30, 2011 | 14.21M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
7.198M
Minimum
Mar 2023
629.39M
Maximum
Sep 2019
135.12M
Average
31.92M
Median
Sep 2021
Cash from Financing (TTM) Benchmarks
| Tonix Pharmaceuticals Holding Corp | 36.52M |
| Amylyx Pharmaceuticals Inc | 3.543M |
| Regulus Therapeutics Inc | 11.82M |
| Minerva Neurosciences Inc | 19.60M |
| Viking Therapeutics Inc | 271.38M |